Carboplatin and granulocyte colony-stimulating factor as first-line treatment for epithelial ovarian cancer: a phase I dose-intensity escalation study. [electronic resource]
Producer: 19950110Description: 1-6 p. digitalISSN:- 0093-7754
- Adenocarcinoma -- drug therapy
- Adult
- Carboplatin -- adverse effects
- Cohort Studies
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Female
- Filgrastim
- Granulocyte Colony-Stimulating Factor -- adverse effects
- Humans
- Leukocyte Count -- drug effects
- Middle Aged
- Neoplasm Staging
- Ovarian Neoplasms -- drug therapy
- Platelet Transfusion
- Recombinant Proteins -- adverse effects
- Thrombocytopenia -- chemically induced
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.